May 21, 2018 / 12:08 PM / in a month

BRIEF-Nabriva Announces Positive Results For Pneumonia Treatment

May 21 (Reuters) - Nabriva Therapeutics PLC:

* NABRIVA THERAPEUTICS ANNOUNCES POSITIVE TOPLINE RESULTS FROM PIVOTAL PHASE 3 CLINICAL TRIAL OF ORAL LEFAMULIN FOR THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA

* NABRIVA THERAPEUTICS PLC - COMPANY PLANS TO FILE A NEW DRUG APPLICATION WITH U.S. FOOD AND DRUG ADMINISTRATION

* NABRIVA THERAPEUTICS PLC - LEFAMULIN MET ALL FDA AND EMA PRIMARY ENDPOINTS AND WAS SHOWN TO BE GENERALLY WELL TOLERATED

* NABRIVA THERAPEUTICS PLC - PLANS TO FILE A NEW DRUG APPLICATION WITH U.S. FOOD AND DRUG ADMINISTRATION IN Q4 OF 2018 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below